

2023

Diagnosis and management of colon cancer patients presenting in advanced stages of complications

Vlad Denis Constantin

Carol Davila University of Medicine and Pharmacy, Department of General Surgery, Bucharest, Romania, constantindenis@yahoo.com

Adrian Silaghi

St. Pantelimon Emergency Hospital, Department of General Surgery, adriansilaghi2014@gmail.com

Dragos Epistatu

Carol Davila University of Medicine and Pharmacy

Anca Silvia Dumitriu

Stana Paunica

See next page for additional authors

Follow this and additional works at: <https://scholar.valpo.edu/jmms>



Part of the [Anesthesiology Commons](#), [Critical Care Commons](#), [Emergency Medicine Commons](#), [Gastroenterology Commons](#), [Oncology Commons](#), and the [Surgery Commons](#)

Recommended Citation

Constantin, Vlad Denis; Silaghi, Adrian; Epistatu, Dragos; Dumitriu, Anca Silvia; Paunica, Stana; Bălan, Daniela Gabriela; and Socea, Bogdan (2023) "Diagnosis and management of colon cancer patients presenting in advanced stages of complications," *Journal of Mind and Medical Sciences*: Vol. 10: Iss. 1, Article 6.

DOI: <https://doi.org/10.22543/2392-7674.1388>

Available at: <https://scholar.valpo.edu/jmms/vol10/iss1/6>

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in *Journal of Mind and Medical Sciences* by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Diagnosis and management of colon cancer patients presenting in advanced stages of complications

Authors

Vlad Denis Constantin, Adrian Silaghi, Dragos Epistatu, Anca Silvia Dumitriu, Stana Paunica, Daniela Gabriela Bălan, and Bogdan Socea

Diagnosis and management of colon cancer patients presenting in advanced stages of complications

Vlad Denis Constantin^{1,2}, Adrian Silaghi^{2*}, Dragos Epistatu³, Anca Silvia Dumitriu⁴, Stana Paunica⁴, Daniela Gabriela Bălan⁵, Bogdan Socea^{1,2}

¹ Carol Davila University of Medicine and Pharmacy, Department of General Surgery, Bucharest, Romania

² St. Pantelimon Emergency Clinical Hospital, Department of General Surgery, Bucharest, Romania

³ Carol Davila University of Medicine and Pharmacy, Department of Radiology, Bucharest, Romania

⁴ Carol Davila University of Medicine and Pharmacy, Dan Theodorescu Hospital, Bucharest, Romania

⁵ Carol Davila University of Medicine and Pharmacy, Department of Physiology, Bucharest, Romania

ABSTRACT



Colorectal cancer is an important health problem with a significant impact on the individual and society. Malignancy (including colorectal cancer) is usually slightly symptomatic in its initial stages. This causes cancer to be discovered in some patients accidentally (either through screening tests in predisposed individuals or during routine investigations for other diseases), while in other patients the colorectal cancer is discovered in late stages, when the symptoms are much more intense due to complications. Unfortunately, such advanced cases of the disease have high rates of morbidity and mortality even with treatment. Current treatment methods are usually complex, interdisciplinary, causing significant suffering (physical, mental) to the individual, while the cost of treatment per patient seems to be extremely high. Until finding therapeutic methods that are effective and accessible to most patients with advanced colorectal cancer, several methods of prophylaxis and early diagnosis should be considered, to reduce as much as possible the devastating impact of this disease. The purpose of this review is to present literature data regarding the current methods of diagnosis and treatment of patients presenting to the doctor with colorectal cancer in advanced stages of complications.

Category: Review

Received: December 18, 2022

Accepted: March 25, 2023

Published: April 25, 2023

Keywords:

colon, cancer, diagnosis, management, advanced stages, complications

*Corresponding author:

Adrian Silaghi,

St. Pantelimon Emergency Clinical Hospital, Department of General Surgery, Bucharest, Romania

E-mail: adriansilaghi2014@gmail.com

Introduction

Tumors have been described since ancient times. For example, in some mummies found in the Middle East and South America, anthropologists have found metastases of an osteosarcoma [1]. As for colon cancer, it was originally studied and described by Hippocrates, who considered that excess black bile was the cause of its occurrence. At that time, in the absence of analgesia and anesthetics, treatment was primarily dietary and symptomatic (administration of tinctures that can relieve pain and/or a mixture of figs and charcoal to stimulate peristalsis in case of occlusive syndrome) [2].

Important steps in understanding the evolution of cancer were made in the following centuries, through the development of a theory according to which the spread of

digestive cancers (especially colon cancer) is mainly via the lymphatic route, a fact later demonstrated by Waldayer [3]. Examining cancer cells under an optical microscope, Muller was later able to differentiate between normal and malignant cells based on their different-looking cell nuclei [4]. With the development of technology, a better understanding of the pathophysiology of cancer and how it metastasizes has been achieved, which has led to the implementation of several surgical and medical therapeutic approaches.

Initially, many substances that were supposed to inhibit the growth and spread of cancer cells (such as mustard gas and lead compounds) were tried for therapeutic purposes [5]. The first effective chemotherapy agent was fluorouracil (discovered in 1957), and the first successful operation was performed by Jacques Lisfranc on a 45-year-

old patient with a rectal tumor [6]. Technological advances have enabled the development of new research theories and models. Thus, nuclear abnormalities were identified in cancer cells, so scientists linked carcinogenesis to DNA mutations. Such mutations would cause not only the appearance of cancer, but also a predisposition of subjects to develop various malignancies, including colon cancer.

All these efforts over the centuries have been driven by an increasing incidence/detection of colon cancer in the general population (being in the top 3 most common cancers in the adult population, both in men and in women), with over 1 million cases currently diagnosed annually [7].

In many cases, symptomatology is nonspecific at onset, such as fatigue and asthenia if the tumor is located on the right colon, while diarrhea and constipation (or their alternation) are more common in patients with tumors of the left colon and rectum. Clinical manifestations are more extensive in the presence of complications (loco-regional invasion with the formation of large tumors that change the relief of the abdominal wall and can be palpated, perforation, hemorrhage, occlusive syndrome or their associations) that determine high rates of morbidity and mortality [8,9].

Colonoscopy is the main diagnostic tool for colon cancer. Due to the low cost of use and increased accessibility, this method can now be used either for the screening of malignant diseases of the rectum and colon, or as a diagnostic and therapeutic method [10]. Current treatments for most patients include surgical resections, with or without adjuvant or neoadjuvant (radio/chemo/immuno-) therapy. For specific cancer forms, targeted genetic and immunological therapies or nanomedicine based on chemotherapeutic agent particles incorporated into various systems (including malignant cells) can also be used, alone or in combination [11]. Regarding complicated colon cancer (hemorrhage, perforation or occlusion), the patient is in a critical general condition (severe anemia, marked inflammatory syndrome with sepsis, etc.), so management is mainly operative and in emergency conditions, with the main goal of saving the patient's life [12].

The aim of the present study is to review the specialized literature on methods of diagnosis and management of patients with colorectal cancer in advanced stages of complications at admission.

Discussions

Epidemiology

Colon cancer is the second most common malignancy in countries with high living standards, causing approximately 50,000 deaths annually in the USA and over 950,000 globally [13,14]. Incidence in the global population tends to be 9.5% of cancers in women and

10.1% in men [15]. The population most prone to develop colorectal cancer is the one with a high economic status, where sedentary lifestyle, obesity and smoking have a high prevalence in the population. Instead, the highest mortality was found in developing countries, as lifestyles are rapidly approaching the Western pattern, while screening programs and access to advanced treatments are still very limited [16].

The stage and type of complications by which colon cancer is discovered significantly influence survival. Thus, patients with small tumors and no lymph node invasion (stage I or II) have a 5-year survival rate of approximately 90% [17]. In contrast, patients presenting in emergency with a complication have a median survival of 59 weeks from the acute event, with perioperative mortality ranging from 5 to 34% and 5-year survival between 12 and 30% [18,19]. The lifetime risk of developing colon cancer varies by sex. The male population has a 0.65% risk, while the female population has a 0.45% lifetime risk of developing colon cancer [20].

Complicated colon cancer can take 3 major clinical forms: perforation, occlusive syndrome, and hemorrhage. Hemorrhage can manifest itself in the form of simple chronic anemia through the constant loss of small amounts of blood, dark-colored stools, or in the form of freshly excreted blood [21]. The complicated form of colon cancer occurs in almost one third of all cases, in which there is usually loco-regional invasion and distant dissemination. They cause a higher rate of tumor recurrence and a higher 5-year mortality rate compared to cases detected in early forms [22]. In perforated forms of colon cancer, the rate of hematogenous metastases is much higher than in other forms of the disease, even if they present the same stage and histological type [23].

As for the risk of developing colon cancer, it is given by two types of factors. Individual/genetic factors cannot usually be modified, while environmental factors can lead to either a decrease in the degree of risk or an increase in it (depending on their nature and action).

Factors that cannot be modified are represented by: age, the 60-79 year group having a 50 times greater risk of developing colon cancer compared to the population under 40 [24]; the presence of inflammatory bowel diseases (both Crohn's disease and ulcerative colitis lead to a risk more than 10 times higher than in the general population, due to inflammation that is localized in the mucosa or the entire wall of the colon) [25], colon history of cancer or adenomatous polyps in the family and the genetic component [26].

The genes involved in the occurrence of colon cancer are represented by MLH1 and MSH2 mutations, which are associated with non-polyposis colon cancer (which represents between 2 and 6% of the entire colon cancer population) but also with other neoplasms such as the

pancreas, kidneys and uterus [27]. APC is a suppressor gene that controls beta-catenin and also interacts with E-cadherin, thereby inhibiting cell growth. When mutated, APC leads to the appearance of familial adenomatous polyposis, characterized by the appearance of numerous colonic polyps that can become malignant; the risk of developing colon cancer during life is 100%, since their malignant transformation begins in the first two decades of life [26].

Environmental factors that can influence the occurrence of colon cancer are largely represented by food. Preparations based on meat or animal fat (prepared at high temperatures) can be degraded by bacterial flora into N-nitroso compounds, polycyclic amines and aromatic hydrocarbons, which have carcinogenic effects [28,29]. Physical activity has a protective role by accelerating the rate of defecation, while smoking predisposes to the appearance of adenomatous polyps which are precursors of colon cancer [30]. Excessive alcohol consumption can induce malignant transformation of cells through its metabolites (acetaldehyde), especially in association with nicotine [31].

The most studied factors that can be influenced are diet and physical activity, which are closely related. By increasing the intake of fiber, fruits and vegetables, there is a reduction in the risk of developing cancer by up to 70% [32]. This effect is obtained due to the increased content of antioxidants, the most important of which are phenols, flavonoids and sulfur products. Such compounds can neutralize free radicals formed as a result of fermentation processes, can influence different cellular or metabolic transmission pathways increasing primary cellular immunity, or can induce apoptosis of premalignant cells [33,34]. Another protective factor against colorectal cancer is the increased intake of whole milk and products derived from it, which can reduce the risk of colon cancer by up to 26% if consumed daily in proportion of 500g/day [35]. It is probably an effect of the increased calcium content that acts as a ligand, trapping saturated fatty acids and bile acids, thus reducing the degree of inflammation in the colonic mucosa [36].

Diagnosis

In the initial stages of the disease, the symptomatology associated with colon cancer is usually nonspecific and of low intensity (in the form of abdominal pain, changes in stool and transit, and/or weight loss). Later, when the disease becomes more advanced, bleeding may occur in association or not with the stool, as well as the palpation of a tumor formation in the abdomen [36]. For a prompt and reliable diagnosis, an anamnesis is necessary (if there are relatives who have suffered from this disease, at what age the cancer started and the cause of death, if there are cases of Lynch syndrome or familial adenomatous polyposis),

after which a colonoscopy with biopsy is necessary to obtain a definite histopathological result [37].

Currently, the gold standard for diagnosis is colonoscopy and biopsies from suspected tissue, which may also be a useful method of treatment for malignantly transformed adenomatous polyps [38]. Because it is an intervention that must be performed by an operator with extensive training, deep learning methods have been developed to help the operator recognize possible tissue abnormalities that require biopsies. The rates of misdiagnosis or non-diagnosis appear to be much lower when software associated with the endoscopy method is used [39].

Endocytoscopy is a relatively new method that evaluates the appearance of the mucosa and submucosa with high resolution by obtaining microscopic images of both cells and even nuclei. It is a method that involves the application of methylene blue, being able to highlight some cellular characteristics such as: the arrangement of the cells, their size and shape, as well as the number of nuclei (or if there is any atypical nucleus) [40]. Regarding cytoendoscopic examination in colon cancer, it has a sensitivity and specificity approaching 95% [41]. Compared to the traditional method of diagnosis with colonoscopy and histopathological examination, there are no differences in lesions larger than 5 mm [42]. In association with artificial intelligence, the sensitivity obtained was over 90% and the specificity over 98% in a group of 200 patients [43].

High-resolution microendoscopy (HRME) is an effective method for investigating the mucosa and submucosal tissue, but it is not yet widely available at present. From a technical point of view, a probe can be placed on the working channel of the endoscope that approaches the tissue to be investigated and histological images are obtained, highlighting the nuclear number, shape and pleomorphism [44]. Regarding colon cancer, HRME has a much higher sensitivity and specificity for detecting potentially malignant adenomatous polyps compared to standard white light endoscopy (94% and 95%, vs. 65% and 39%) [45].

Blood tests, urine and stool samples have the advantage of being easy to collect and without creating a pronounced discomfort for the patient, so numerous methods have been developed to identify patients with colon cancer (some of them with an even very accurate large, similar to pathological examination). APC, K-ras, p53, Bcl-2 Cyclin D1, E1 and microRNA/DNA can be identified in stool, blood, urine, even in breath via volatile products [46,47].

One of the new diagnostic markers developed for colon cancer is circulating DNA as a result of cell apoptosis. Most of the time, the sizes of these chains of nitrogenous bases reach the number of 180, while in patients with cancer of any type the fragments are larger [48]. By

forming a ratio between the number of long and short DNA chains, the integrity of cellular DNA can be identified. A 25- to 50-fold increase in the ratio is observed in colon cancer patients compared to the healthy population [49]. Thus, quantitative PCR analysis of DNA microchains has a sensitivity of 73.1% and a specificity of 91.8% [50]. Unlike DNA, RNA chains of about 20 bp are more stable, being harder to degrade endogenously and can withstand variable pH values [51]. Thus, various batteries have been developed for the recognition of circulating mircoRNA, including the colorectal cancer, which can reach sensitivities of over 90%. The association of Mi-24, Mi-320a and Mi-423-5q (preformed RNA sequences) leads to a sensitivity of 92.8% and a specificity of 70.8% in the diagnosis of colorectal cancer [52].

Another type of markers that can be used in colorectal cancer are hypoxia-inducible factor (HIF) and 1-alpha-antisense RNA-1, which have high specificity, establishing the diagnosis in 151 cases out of 160 [53].

Colorectal neoplasia differentially expressed-h (CRNDE-h) is a marker that can diagnose colon cancer. Comparing with CEA marker, it can better differentiate the suspected patients from the healthy individuals and can also be used as a prognostic marker. Its increased values are associated with lymph node metastases, and with a lower 5-year survival compared with those who have borderline levels [54].

Slit-Like 2 is a transmembrane protein (also known as Vasorin) that can be found in aortic smooth muscle fibers, as well as in breast, hepatocellular or prostate cancers, where it has a role in promoting tumor growth and invasion [55,56]. In colon cancer, high levels of this marker were found compared to the control group, the higher values being correlated with advanced disease. Values between 75.54 ± 5.70 pg/mL occur in the normal population, while values between 252.81 ± 76.82 pg/mL are frequently found in patients with tumors placed on the colon [57].

Although they have lower specificities and sensitivities, non-invasive tests collected from faecal matter have the advantage of being fast, cheap and easy to use even by patients. The first of the stool-collected tests was the Guaiac stool test, which can identify small amounts of blood in the stool, reducing mortality by 10-20% in tested patients by faster detection of colon tumors [58]. Unfortunately, the sensitivity and specificity of this test are around 40% [59], being not able to differentiate between human and animal heme or whether the hemorrhage is above or below the Treitz angle [60]. An improvement of this test was the faecal immunochemical test which recognizes human hemoglobin only in very small amounts (only one test being required) so that bleeding lesions (adenomatous polyps, diverticula, etc.) can be identified [61].

Apart from the presence of blood in the stool as a result of an adenomatous polyp or a tumor lesion, another

diagnostic element can be represented by the presence of genetic material in the form of DNA/RNA. About 0.1% of the DNA in the stool is from the colonic mucosa, the rest being bacterial or from food [62]. The Cologuard test is the only test that recognizes tumor DNA and is currently used as a screening method in colorectal cancer. It has much better sensitivity and specificity than faecal occult blood tests [63].

Alteration of cellular metabolism in a neoplastic patient can lead to waste products that can be gaseous at room temperature and can be detected in the various eliminated products of patients, such as urine, exhaled air or feces [64]. Urine from cancer patients was examined by gas chromatography and field asymmetric ion mobility spectrometry, and degradation products with molecular masses up to 1500 daltons were identified [65]. These methods have a sensitivity between 68 and 89% and a specificity of 60% when used in association.

Regarding the volatile products emanated through feces, in colon cancer hydrogen sulfide is involved in carcinogenesis through direct effects on the cells of the colonic mucosa and via the alteration of the microbiota at this level [66,67]. Other volatile products identified in patients with colon cancer are those derived from acetone such as propan-2-ol and hexan-2-one resulting as a reaction between ethanol and 3-methylbutanoic [68], methyl mercaptan which was found in large quantities in those who had advanced stages of the disease as a result of the reaction between amino acids with sulfur and lactic acid produced by cancer cells [69].

Regarding the volatile products emitted by feces, in colon cancer hydrogen sulfide is involved in carcinogenesis through direct effects on the cells of the colonic mucosa and by altering the microbiota at this level [67]. Other volatile products identified in colon cancer patients are those derived from acetone, such as propan-2-ol and hexan-2-one, which result from the reaction between ethanol and 3-methylbutanoic acid [68]. Methyl mercaptan has been found in large amounts in those with advanced disease stages as a result of the reaction between aminoacids with sulfur and lactic acid produced by cancer cells [69].

Numerous volatile compounds can be eliminated through breathing, colon cancer patients being more easily identified by changing the ratio of these volatile products. Thus, gas chromatography found higher levels of ethyl acetate compared to the healthy population and identified lower levels of 4-methyloctane, with a sensitivity of 85% and a specificity of 95%, with an accuracy of 91% [70]. Secondary to these results, gas chromatographic examination of breath can be used as a future screening method for colorectal cancer, the only drawbacks being the lack of a universal protocol for device calibration and the limited availability of the necessary equipment [66].

Treatment of complicated forms of colon cancer

Occlusion and hemorrhage are the most common surgical complications/ emergencies of colon cancer. If the general condition of the patient is good and there is no dissemination (local or distant), curative surgical oncological treatment should be performed [71,72]. From an anatomical point of view, the occlusion of the colon can be proximal (if the formation is on the transverse or ascending colon, up to the splenic flexure) or distal (if the tumor is located on the descending and sigmoid colon). These tumors placed on distinct segments of the colon have different treatments, due to distinct embryological and anatomical characteristics. Stenotic tumors occur more frequently in the left colon because it is smaller in diameter and the stool is generally solid (due to greater water absorption), so the occlusive complication is more common in the left colon [73]. In contrast, the right colon is much larger in diameter and the contents are semisolid. Tumors placed at this level are frequently voluminous and invade adjacent structures, the most frequent complication of tumors located on the right colon being hemorrhage.

Surgical treatment in the case of obstructive tumors of the right colon is represented by right hemicolectomy, with ligation at the origin of the ileo-colic arteries, of the right colic arteries, and of the right branch of the middle colic artery, followed by the restoration of digestive continuity through ileo-colic anastomosis. If the tumors are placed distally on the right colon, an extended right hemicolectomy with ligation of the middle colic artery at the origin is required, which would involve extensive resection and more distal anastomosis [18]. Postoperative complications that may occur in emergency patients are higher, with the rate of post-anastomotic fistulas estimated to be between 2.8 and 4.6% compared to 1-2% in elective operations [74].

Minimally invasive laparoscopic treatment of obstructive colon cancer can achieve the same oncological standards in terms of complication rate and survival. The 30-day mortality of patients who underwent laparoscopic resections was better than those who underwent the classical surgical approach, while oncological outcomes were similar. Comparing the number of nodes removed, the recovery rate, and the amount of blood lost, the outcome was much more favorable in the case of the laparoscopically treated group [75].

Distal occlusion is more clinically evident because the consistency of fecal chyme is greater and the diameters at this level are smaller, so a small tumor can cause intestinal obstruction in relatively early stages of the disease. Therapeutic modalities in this case vary, from continuous colostomy, Hartman resection, resection with anastomosis, colonic stenting, etc. [18].

Regarding the placement of the continuous colostomy, it can be performed either as a definitive treatment (in

advanced cases) or as an intermediate therapeutic stage (in which the patient must first be rebalanced and stabilized). After stabilization, the patient is treated by oncological methods, to transform the tumor into a resectable stage. Afterwards, the tumor is resected and the continuity of the digestive tube is restored. It is a simple treatment method that can be performed even with local anesthesia, but the rates of peristomal complications are relatively high (due to the risk of prolapse or parastomal hernia, especially when performed as an emergency) [76].

Resection of the tumor placed in the left colon, followed by colostomy at the proximal end and closure of the distal end is known as the Hartman operation (a type of surgical procedure commonly performed for obstructive tumors of the distal colon) [77]. Currently, there are no significant differences in the long-term evolution of patients in the colostomy group compared to those who followed a sequential therapy, in the latter case, however, the time spent in the hospital being longer [78]. The main disadvantage of this intervention is the presence of residual stoma, which leads to a decrease in the quality of life secondary to local complications. In 20% of cases, the restoration of normal digestive transit is not performed by closing the colostomy, because there is a high risk of morbidity and mortality, as well as a higher risk of local recurrence [79].

The indications for the Hartmann procedure are aimed at patients with high anesthetic risk scores in whom the time of presentation to the hospital is late (the evolution of the disease being associated with significant distension of the colon), and patients with high operative risk in whom a staged surgical approach could lead to the decompensation of some severe systemic (cardiac, pulmonary, renal, hepatic, etc.) comorbidities [80-82].

In the case of obstructive colon cancer, it is therefore preferable for the patient to undergo a unique surgical intervention (resection with anastomosis), thus maintaining the quality of life as before the operation. For a long time, it was considered risky to perform an anastomosis in the case of patients with occlusive tumors, due to the marked distension of the digestive segments associated with an altered state of nutrition. These factors predispose to the occurrence of anastomotic fistulas (with high morbidity and mortality rates), which can cause prolonged hospitalization that delays the initiation of chemotherapy [18]. Currently, it is considered that the method of resection and anastomosis in the same time should be applied only to well-selected patients, in order to reduce the large number of surgical interventions secondary to complications [76]. Such factors that influence the possibility of performing an anastomosis in emergency cases are: age >70 years, high anesthetic risk (ASA III-IV), if the disease is in an advanced phase, the presence of preoperative renal insufficiency or other

systemic comorbidities. When several such unfavorable factors are associated, it is necessary to perform a colostomy or a Hartmann-type surgical procedure [83].

Another therapeutic option in the case of stenotic tumors is represented by the installation of metal stents in the affected area, being used either as a palliative method (in cases of unresectable tumors), or as a transitional therapy until the patient is stabilized in order to have an optimal (local and general) operator status [84].

Some authors recommend avoiding the placement of stents as a temporary treatment, as there are suspicions that it could negatively influence the long-term outcome. By installing the dilating stent, there could be microperforations in the colon wall that would lead to transperitoneal spread and thus a higher risk of peritoneal dissemination and carcinomatosis. Another possible consequence of the mechanical action of the stent would be the migration of tumor cells through the microcirculation with hematogenous dissemination [85-87]. However, the morbidity and mortality rates of patients with preoperative stent placement appear to be similar to those of electively operated patients, with the rate of anastomosis being relatively comparable [84]. Another advantage of this minimally invasive treatment is the lower rate of performing colostomies, while the number of nodes harvested for histopathological evaluation was similar to that corresponding to scheduled surgical interventions [88].

From a technical point of view, difficulties may arise in terms of stent placement and functionality, especially if the stenotic portion exceeds 8 cm and its placement requires the installation of a guide system to reach the area of stenosis [89].

Cancer placed in the rectum and causing an occlusive syndrome has the same principles of treatment as the tumor located in the left colon. Thus, a colostomy can be done for decompression, but this involves sacrificing a few centimeters of intestine that would be necessary in the case of a low anastomosis. An alternative to this inconvenience is the formation of an ileostomy, but with the risk of creating an isolated loop if the ileo-cecal valve is competent [18]. Another option for patients with stenosing formations at the level of the recto-sigmoid junction or in the upper rectal region is the Hartman procedure. This has curative potential, but with the risk of putting the patient in the situation of a definitive colostomy, because restoring the continuity of the digestive tube through anastomosis is very rare. Metal stents can be mounted as a palliative method also at the level of the rectum, but this maneuver is risky due to the increased peristalsis at this level that can lead to the migration of the metal device and the induction of rectal wall lesions [90].

Another complication that can develop in the evolution of colon cancer is represented by the perforation of the colon wall (secondary to the ischemia and necrosis of the

tumor tissue) or by distant (diastatic) perforation due to the upstream phenomenon of distension of the colon [91]. Such colonic perforations lead to acute fecaloid peritonitis, a clinical entity with high mortality that can reach up to 50% (secondary to septic shock with multiple organ failure) [92]. One of the factors that influence mortality in the case of peritonitis by perforation of a tumor is the blood pressure value, a value below 80 mmHg (especially in the elderly) being a negative prognostic factor [18].

The clinical features of this complication are those of an acute abdomen, so the strategy must be based on a surgical intervention aimed at controlling/ treating the lesion. This is possible by performing a laparotomy/ laparoscopy, with identification of the perforated area followed by resection of the affected segment. Even if there is no data to suggest a preoperative diagnosis of malignancy, surgery will be performed (where possible) according to the principles of oncological surgery. If resectable liver metastases are present, they can be resected only if the general condition of the patient allows extensive surgery. In most cases, the anastomosis cannot be performed, the ileostomy being the final result of the intervention. If an attempt is made to restore the continuity of the digestive tract during the first operative time, an upstream protective stoma is recommended [93].

Diastatic perforation of the cecum occurs secondary to severe vascular disorders, caused by the massive distension of this digestive segment as a result of a stenotic tumor located downstream. In this case, a subtotal or even total colectomy is performed excluding both lesions of the digestive tract with stoma formation, or with ileo-colic or ileo-rectal anastomosis if the patient is not in a high-risk group [94].

Minimally invasive treatment for perforated colon cancer can also be performed through laparoscopic procedures. Patients operated with this method had a shorter hospital stay, a quick return to activities, less blood loss, all with oncological results relatively similar to open surgery but with a longer operative time. After the creation of pneumoperitoneum, several factors can intervene and complicate the therapeutic approach (massive contamination of the peritoneal cavity with dilated intestinal loops and multiple adhesions, which makes it difficult to assess the location of the perforation even using an effective peritoneal lavage). Consequently, especially for surgical teams that are not as well trained as for elective interventions, the expected results may not be as good as those in centers of excellence. For this reason, it is recommended that laparoscopy be used only by trained teams (with at least 20 previously operated cases, who can easily overcome any technical difficulties that may arise), to lead to the best postoperative therapeutic results [95].

Lower gastrointestinal bleeding is a syndrome characterized by the passage of fresh or partially digested

blood in the stool. Colon cancer can present this form of complication in 3-11% of cases [96]. Most of the time, lower gastrointestinal bleeding is small, self-limited, which can alarm patients early, bringing them to the doctor at an early stage of the disease [97]. The initial management of this syndrome is represented by stabilizing the patient, correcting his various biochemical abnormalities such as coagulopathy, dyselectrolytemia and, subsequently, finding the source of the bleeding [21]. This can be done by endoscopic methods, but in an emergency situation (with an unprepared colon) the source can only be identified in 74-89% of cases [98]. The advantage of colonoscopy is that this method can be used not only to identify, but also to treat the cause of bleeding. Among the endoscopic treatment methods listed in the literature are devices that use thermal energy to achieve coagulation with or without contact, radiofrequency ablation, endoloops, injection of various sclerosing or hemostatic agents, and hemospray [99].

The thermal methods that assume direct contact with the tumor are by far the most used, through which a good local hemostasis is achieved initially, especially if it is associated with the local administration of norepinephrine. Approximately 30 days after the intervention, bleeding can reappear with rates that can reach up to 80%, thus being a useful therapeutic method especially for the preparation of a subsequent surgical intervention [100].

The injection of sclerosing or procoagulant substances was the first endoscopic method of performing hemostasis, being used even today in the control of upper digestive hemorrhages or in the case of hemorrhagic colon tumors. The most used agent is adrenaline as a solution with a dilution of 1:10,000, having both vasoconstrictor and thrombogenic effect [101]. The use of other agents, such as alcohol, appears to be correlated with high rates of ischemic necrosis and tumor perforation [102].

Angiography is an intervention capable of identifying the source of bleeding and treating it by selectively embolizing the vessels that supply blood to the respective tumor. Different hemostatic agents such as vasopressin or gelatin particles are used for injection, methods that have success rates of approximately 70% [103]. The main disadvantage of this method is the increased risk of ischemia and necrosis. Consequently, angiography is mainly used as a diagnostic method, or as a therapeutic method for cases where there are distant metastases and multiple comorbidities, thus preventing laparotomy (for bleeding control) that would delay the administration of chemotherapy [98].

The natural evolution of colon cancer is aggravated by the occurrence of distant metastases, the most frequently affected organs being the liver, peritoneum, lung and brain (either by lymphatic or hematogenous route). The appearance of two colonic tumors can be considered

metastasis if the respective tumors have the same cellular/molecular characteristics [104]. Through a multimodal treatment (surgery, chemotherapy, radiotherapy, immunotherapy, genetic, biological support, etc.), colon cancer can be completely eliminated in some patients even in advanced stages, thus obtaining appreciable survival rates at 5 years. All this can be achieved by a complete evaluation of patients with genomic evaluation of tumor cells, including RAS and BRAF gene status [105].

Liver metastases often occur in patients with colon tumors whose cells overexpress genes encoding MMP-1, MMP-2, COX-2, TIMP-1, VEGF [106,107]. Resection of these metastases without preoperative chemotherapy is recommended, as this therapy has no benefit in terms of patient survival at 5 years, while complication rates appear to be higher in patients who received the chemotherapy regimen [108].

If liver metastases are discovered at the same time as the primary tumor, there are several therapeutic options. When the tumor is symptomatic (complicated by either occlusive syndrome or bleeding) and the metastases are resectable, emergency surgical procedure is required only to treat the local complication. It is followed by systemic chemotherapy, and finally the surgeon proceeds to resect the remaining liver metastases. Regarding occlusive rectal cancer where radiotherapy plays an important role, a colostomy can be performed initially, after which the oncological treatment is initiated which is finally followed by the resection of the liver metastasis [105].

For asymptomatic colon tumors with hepatic metastases, a 6-course cycle of chemotherapy can be initiated, after which the colon tumor and remaining hepatic metastases are resected in the same surgical procedure [109]. The postoperative course is without major complications or an increased mortality, if the surgical intervention does not involve major liver resections [110].

The criteria for resection of liver metastases elaborated by the American Hepato-Pancreato-Biliary Association are represented by the absence of tumor cells in the resection margin of the tumor, the preservation of liver function, the limited presence of extrahepatic disseminations (which can eventually be resected), lack of disease progression during chemotherapy, as well as the ability of the patient to be fit for major surgery [111]. If the patients are at the limit of a possible liver resection, chemotherapeutic treatment can be administered beforehand, thus transforming the initial oncological stage into a stage much more favorable for surgical intervention. These complex therapeutic approaches result in a 5-year survival of 50%, with perioperative mortality rates below 3% [112].

Regarding the surgical treatment of choice, most operators opt for partial hepatectomy [113]. Limited resections are associated with lower rates of postoperative

complications and morbidity, a shorter length of time spent in the intensive care unit, and a lower rate of liver failure [114,115].

For advanced cases with large or disseminated tumors in both liver lobes, hypertrophy of the remaining liver parenchyma can be done by so-called two-stage hepatectomy. It is an intervention associated with high risks, but it can be performed in experienced centers. In the first stage, all tumor formations in segments 2 and 3 are resected, then the right portal branch is ligated, which causes hypertrophy of the remaining parenchyma for 6-12 months. Subsequently, a second resection is performed, which removes all other metastatic formations [116]. In the period of controlled hypertrophy of the liver parenchyma, it is important to follow the growth rate, because an increase of more than 2% per week is a negative impact factor for the second intervention (higher risks of liver failure) [117]. Completion of second-stage resection leads to an increase in median survival of approximately 11 months (37 vs. 16) [118].

Regarding the laparoscopic approach to liver metastases, several studies have compared this minimally invasive method with classical open surgery. Patients who were included in the laparoscopic group had a lower rate of postoperative complications (19% vs. 31%), with lower rates of hospitalization (53h vs. 96h) and less need for narcotics for pain control. The time spent in the operating room was approximately equal, but with a lower blood requirement in the laparoscopically treated group. The cost of the interventions was higher in the case of laparoscopic interventions, but with a better postoperative recovery and a shorter length of hospital stay, thus reaching an approximately equal total cost per patient [119]. After surgery, patients were evaluated for several factors that could predict long-term surgical success, so quality of life was better in the laparoscopically treated group in many respects. This comparison included emotional, physical and social aspects [120]. Recurrence rates ranged between 62-67% in both cohorts of patients with lung, liver and peritoneal metastases, with the factors considered leading to recurrence being the presence of extrahepatic metastases and lymph node invasion [119].

The synchronous approach to both the primary tumor and liver metastases can be done by classical or laparoscopic methods. In a meta-analysis performed in dedicated centers in France, Spain, Israel, UK, Italy, South Korea, survival, feasibility and patient risks were analyzed. Similar rates were obtained in terms of blood loss rates and transfusion, but with longer operating times in the case of laparoscopic operations. Out of the total of 20 laparoscopic interventions, only one was converted to classical surgery, the reason being the appearance of technical defects and intraoperative incidents. Major preoperative complications were encountered in 20% of cases, with no difference in

the mortality rate (only 4 deaths out of 490 patients were recorded). Length of hospital stay ranged from 6 to 16 days for both cohorts. At 3 years post-intervention, no differences in survival rates were observed between the 2 cohorts, which means that, from an oncological point of view, the laparoscopic approach is similar to open surgery, but with better results in terms of safety, survival rates, bleeding and postoperative complications. Not all patients were approached laparoscopically, as this type of approach was used mostly for antero-lateral resections compared to posterior ones [119].

Metastasis of colon cancer at the peritoneal level occurs in 11% of patients [121], the last stage of the disease being the appearance of peritoneal carcinomatosis. It is considered a final stage that requires palliative and supportive nutritional treatment for the patient. Most of the time, it is associated with dissemination to other organs, and if more than 2 sites of metastasis are involved, the prognosis is severe, as they generally show BRAF gene mutations much more frequently [122].

Thus, the average survival time without treatment varies between 5.2 and 12.6 months [123], and with treatment it can reach 12.7 months. With an average duration of 5.8 months without disease progression [124], biological treatments can be administered (bevacizumab, cetuximab) which have proven their effectiveness by obtaining better survival rates [125].

The first therapeutic method described for peritoneal dissemination of malignant disease is an association of hyperthermic intraperitoneal chemotherapy with cytoreductive treatment, which aims at the resection of all visible tumors along the visceral and parietal peritoneum associated with complete peritonectomy [126]. Cytoreductive surgery is associated with a significant rate of mortality and morbidity [127], has an average duration of 7-10 hours and involves 12-17 days of hospital stay [128]. Good patient selection is required, and despite this, approximately half of subjects develop rapid disease progression, reaching up to 70% within the first 2 years of disease [129].

Regarding the surgical point of view, the interventions start with the resection of the greater omentum, peritoneum from the left and right quadrants along with the resection of the small omentum, the gallbladder, but also the resection of the pelvic peritoneum, and in selected cases a splenectomy can be required [126]. After the resections, 3 liters of normal saline solution are introduced at a temperature of 42.5 degrees Celsius together with a chemotherapeutic agent: Mitomycin c 40 mg for 90 minutes [130]. The results of the associated treatment are favorable, a combined therapy offering a survival rate of nearly 22.3 months but associated with high risks [131].

Lung metastases are quite rare in the evolution of colon cancer but slightly more frequent in rectal cancer (whose cells express markers such as RAS and CXCR7, while at

the cellular level there is an increased activity of the WNT pathway) [132]. In the occurrence of pulmonary dissemination, the prognosis is poor (most patients do not survive beyond 24 months), with a 5-year survival rate of 1.9%. If extrapulmonary metastatic sites are also present, the patient's prognosis is much worse. In selected cases, surgical treatment with resection is attempted, with survival reaching up to 56% [133] with this management mode, but the recurrence rate after 2 years tends to be 80% [134]. Resection of pulmonary metastases is done with the intention of preserving as much functional parenchyma as possible (atypical resections), and in most cases lymphadenectomy is performed only in the case of suspicious and large nodes that can cause compression phenomena [135].

Conclusions

Colon cancer has a continuously increasing incidence, due to changes in lifestyle that tend to favor the appearance and development of the disease. An early detection of colorectal cancer through appropriate screening methods at the population level (which must be cheap, accessible, but including modern diagnostic and treatment technologies) could lead to a decrease in the level of mortality and morbidity in the case of colon cancer and rectum.

One of the most feared complications of colorectal cancer (in terms of survival, morbidity, and mortality) is perforation, which is associated with high perioperative complications/risks and a very high recurrence rate. Intestinal obstruction must be recognized early by the patient, being manifested by the progressive decrease in transit followed by the absence of stool for several days (signs that should alarm the patient and prompt him to see a doctor as soon as possible). Bleeding from colorectal tumors, although not as severe as upper gastrointestinal bleeding, should be a compelling enough sign to prompt the patient to see a doctor. Even colorectal cancer detected in advanced stages (loco-regional dissemination and distant metastases) should prompt the patient to follow a specific treatment, because recent advances made and implemented in the form of modern treatments can favorably manage such cases, offering good rates of survival and a satisfactory level of quality of life.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

References

1. Spoială A, Ilie CI, Motelica L, et al. Smart Magnetic Drug Delivery Systems for the Treatment of Cancer. *Nanomaterials (Basel)*. 2023;13(5):876. Published 2023 Feb 26. doi:10.3390/nano13050876
2. Mulcahy HE, Hyland J, O'Donoghue DP. From dinosaurs to DNA: a history of colorectal cancer. *Int J Colorectal Dis*. 2003;18(3):210-215. doi:10.1007/s00384-002-0461-0
3. Waldeyer-Hartz HWG. Die Entwicklung der Carcinome. *Virchows Arch Pathol Anat*. 1867;41:470–523.
4. Recamier JCA. Recherches sur le traitement du cancer, par la compression methodique simple ou combinee, et sur l'histoire generale de la meme maladie. Gabon, Paris. 1829; pp. 1774-1852.
5. Bell WB. Lead in the Treatment of Malignant Disease. *Br Med J*. 1926 Apr 10;1(3406):675.
6. Lisfranc MJ. Mémoire sur l'excision de la partie inférieure du rectum, devenue carcinomateuse. *Repr. from Gaz. méd. Paris*, vol. i, 1830.
7. Motofei IG. Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation. *Semin Cancer Biol*. 2022;86(Pt 3):600-615. doi:10.1016/j.semcancer.2021.10.003
8. Milluzzo SM, Bizzotto A, Cesaro P, Spada C. Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions. *Expert Rev Anticancer Ther*. 2019;19(1):71-80. doi:10.1080/14737140.2019.1538798
9. Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. *Mol Oncol*. 2019;13(2):109-131. doi:10.1002/1878-0261.12417
10. Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. *Gut*. 2018;67(2):291-298. doi:10.1136/gutjnl-2016-312712
11. Kotelevets L, Chastre E, Desmaële D, Couvreur P. Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. *Int J Pharm*. 2016; 514(1):24-40. doi:10.1016/j.ijpharm.2016.06.005
12. Cao Y, Deng S, Wu K, et al. Oncological consequence of emergent resection of perforated colon cancer with complete obstruction after stent insertion as a bridge to surgery. *Int J Colorectal Dis*. 2019;34(3):545-547. doi:10.1007/s00384-018-3137-0
13. Herbert C, Paro A, Diaz A, Pawlik TM. Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates Among US Counties. *Ann Surg Oncol*. 2022; 29(2):837-848. doi:10.1245/s10434-021-10849-7

14. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut*. 2017;66(4):683-691. doi:10.1136/gutjnl-2015-310912
15. Hagggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg*. 2009;22(4):191-197. doi:10.1055/s-0029-1242458
16. Sawicki T, Ruskowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers (Basel)*. 2021;13(9):2025. Published 2021 Apr 22. doi:10.3390/cancers13092025
17. Dumitru FA, Micu SI, Popoiag RE, Musat M, Caloian AD, Calu V, Constantin VD, Balan DG, Nitipir C, Enache F. Intestinal dysbiosis – a new treatment target in the prevention of colorectal cancer. *J Mind Med Sci*. 2021;8(2):221-228. doi:10.22543/7674.82.P221228
18. Baer C, Menon R, Bastawrous S, Bastawrous A. Emergency Presentations of Colorectal Cancer. *Surg Clin North Am*. 2017;97(3):529-545. doi:10.1016/j.suc.2017.01.004
19. Ho YH, Siu SK, Buttner P, Stevenson A, Lumley J, Stitz R. The effect of obstruction and perforation on colorectal cancer disease-free survival. *World J Surg*. 2010;34(5):1091-1101. doi:10.1007/s00268-010-0443-2
20. Motofei IG. Biology of Cancer; From Cellular Cancerogenesis to Supracellular Evolution of Malignant Phenotype. *Cancer Invest*. 2018;36(5):309-317. doi:10.1080/07357907.2018.1477955
21. Barnett A, Cedar A, Siddiqui F, Herzig D, Fowlkes E, Thomas CR Jr. Colorectal cancer emergencies. *J Gastrointest Cancer*. 2013;44(2):132-142. doi:10.1007/s12029-012-9468-0
22. Yang KM, Jeong MJ, Yoon KH, Jung YT, Kwak JY. Oncologic outcome of colon cancer with perforation and obstruction. *BMC Gastroenterol*. 2022;22(1):247. Published 2022 May 15. doi:10.1186/s12876-022-02319-5
23. Weixler B, Warschkow R, Ramser M, et al. Urgent surgery after emergency presentation for colorectal cancer has no impact on overall and disease-free survival: a propensity score analysis. *BMC Cancer*. 2016;16:208. doi:10.1186/s12885-016-2239-8
24. Tudosie MS, Pauna A, Stefani C, Staicu IM. Diet and Food chemicals increasing the risk of colorectal cancer – literature review. *J Mind Med Sci*. 2022;9(1):118-124. doi:10.22543/7674.91.P118124
25. Janout V, Kollárová H. Epidemiology of colorectal cancer. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2001 Sep;145(1):5-10. doi:10.5507/bp.2001.001
26. Orlov-Slavu C, Parosanu A, Olaru M, et al. How opportune is multigene testing in metastatic colorectal cancer? A review. *J Mind Med Sci*. 2021;8(2):215-220. doi:10.22543/7674.82.P215220
27. Ohki D, Yamamichi N, Sakaguchi Y, Takahashi Y, Kageyama-Yahara N, Yamamichi M, Takeuchi C, Tsuji Y, Sakai Y, Sakurai K, Tomida S, Koike K, Fujishiro M. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. *Cancer Med*. 2022 Dec;11(24):5066-5078. doi:10.1002/cam4.4810
28. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. *Int J Cancer*. 2006 Dec 1;119(11):2657-64. doi:10.1002/ijc.22170
29. Sinha R. An epidemiologic approach to studying heterocyclic amines. *Mutat Res*. 2002;506-507:197-204. doi:10.1016/s0027-5107(02)00166-5
30. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. *Gastroenterology*. 2008;134(2):388-395. doi:10.1053/j.gastro.2007.11.007
31. Pöschl G, Seitz HK. Alcohol and cancer. *Alcohol Alcohol*. 2004;39(3):155-165. doi:10.1093/alcalc/agh057
32. Willett WC. Diet and cancer: an evolving picture. *JAMA*. 2005 Jan 12;293(2):233-4. doi:10.1001/jama.293.2.233. PMID: 15644551.
33. Baena R, Salinas P. Diet and colorectal cancer. *Maturitas*. 2015;80(3):258-264.
34. Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM, Spandidos DA. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. *Pharmacol Ther*. 2010;126(1):9-20. doi:10.1016/j.pharmthera.2010.01.009
35. Ralston RA, Truby H, Palermo CE, Walker KZ. Colorectal cancer and nonfermented milk, solid cheese, and fermented milk consumption: a systematic review and meta-analysis of prospective studies. *Crit Rev Food Sci Nutr*. 2014;54(9):1167-1179. doi:10.1080/10408398.2011.629353
36. Kuang H, Sun X, Liu Y, et al. Palmitic acid-induced ferroptosis via CD36 activates ER stress to break calcium-iron balance in colon cancer cells. *FEBS J*. 2023;10.1111/febs.16772. doi:10.1111/febs.16772
37. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut*. 2015;64(10):1637-1649. doi:10.1136/gutjnl-2014-309086
38. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. *N Engl J Med*. 2006;355(18):1863-1872. doi:10.1056/NEJMoa054967
39. Zhou D, Tian F, Tian X, et al. Diagnostic evaluation of a deep learning model for optical diagnosis of colorectal cancer. *Nat Commun*. 2020;11(1):2961. doi:10.1038/s41467-020-16777-6

40. Bhushan S, Richards-Kortum R, Anandasabapathy S. Progress and Challenges of Global High-Resolution Endoscopy. *Int Arch Intern Med.* 2020;4(1):024. doi.org/10.23937/2643-4466/1710024
41. Sasajima K, Kudo SE, Inoue H, et al. Real-time in vivo virtual histology of colorectal lesions when using the endocytoscopy system. *Gastrointest Endosc.* 2006; 63(7):1010-1017. doi:10.1016/j.gie.2006.01.021
42. Mori Y, Kudo S, Ikehara N, et al. Comprehensive diagnostic ability of endocytoscopy compared with biopsy for colorectal neoplasms: a prospective randomized noninferiority trial. *Endoscopy.* 2013; 45(2):98-105. doi:10.1055/s-0032-1325932
43. Takeda K, Kudo SE, Mori Y, et al. Accuracy of diagnosing invasive colorectal cancer using computer-aided endocytoscopy. *Endoscopy.* 2017;49(8):798-802. doi:10.1055/s-0043-105486
44. Pierce M, Yu D, Richards-Kortum R. High-resolution fiber-optic microendoscopy for in situ cellular imaging. *J Vis Exp.* 2011;(47):2306. doi:10.3791/2306
45. Parikh ND, Perl D, Lee MH, et al. In vivo classification of colorectal neoplasia using high-resolution microendoscopy: Improvement with experience. *J Gastroenterol Hepatol.* 2015;30(7):1155-1160. doi: 10.1111/jgh.12937
46. Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA, Francis NK. Biomarkers for early detection of colorectal cancer and polyps: systematic review. *Cancer Epidemiol Biomarkers Prev.* 2014;23(9):1712-1728. doi:10.1158/1055-9965.EPI-14-0412
47. Wang C, Ke C, Wang X, et al. Noninvasive detection of colorectal cancer by analysis of exhaled breath. *Anal Bioanal Chem.* 2014;406(19):4757-4763. doi: 10.1007/s00216-014-7865-x
48. Motofei IG. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches. *Curr Treat Options Oncol.* 2019;20(6):45. Published 2019 May 6. doi:10.1007/s11864-019-0643-4
49. Frattini M, Gallino G, Signoroni S, et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. *Ann N Y Acad Sci.* 2006;1075: 185-190. doi:10.1196/annals.1368.025
50. Wang X, Shi XQ, Zeng PW, Mo FM, Chen ZH. Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis. *Oncotarget.* 2018;9(36):24514-24524. doi: 10.18632/oncotarget.25314
51. Berger F, Reiser MF. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?. *Theranostics.* 2013;3(12):943-952. Published 2013 Nov 30. doi:10.7150/thno.7445
52. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One.* 2011;6(3):e17745. doi:10.1371/journal.pone.0017745
53. Gong W, Tian M, Qiu H, Yang Z. Elevated serum level of lncRNA-HIF1A-AS1 as a novel diagnostic predictor for worse prognosis in colorectal carcinoma. *Cancer Biomark.* 2017;20(4):417-424. doi:10.3233/CBM-170179
54. Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. *Oncotarget.* 2016;7(51):85551-85563. doi:10.18632/oncotarget.13465
55. Li S, Li H, Yang X, et al. Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum. *Oncotarget.* 2015;6(12):10045-10059. doi: 10.18632/oncotarget.3541
56. Cui FL, Mahmud AN, Xu ZP, Wang ZY, Hu JP. VASN promotes proliferation of prostate cancer through the YAP/TAZ axis. *Eur Rev Med Pharmacol Sci.* 2020; 24(12):6589-6596. doi:10.26355/eurrev_202006_21644
57. Aydin M, Kızıltan R, Algul S, Kemik O. The Utility of Serum Vasorin Levels as a Novel Potential Biomarker for Early Detection of Colon Cancer. *Cureus.* 2022;14(1):e21653. Published 2022 Jan 26. doi: 10.7759/cureus.21653
58. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. *Gastroenterology.* 2004;126(7):1674-1680. doi: 10.1053/j.gastro.2004.02.018
59. Valori R, Rey JF, Atkin WS, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Quality assurance in endoscopy in colorectal cancer screening and diagnosis. *Endoscopy.* 2012;44 Suppl 3:SE88-SE105. doi:10.1055/s-0032-1309795
60. Kuipers EJ, Rösch T, Bretthauer M. Colorectal cancer screening--optimizing current strategies and new directions. *Nat Rev Clin Oncol.* 2013;10(3):130-142. doi:10.1038/nrclinonc.2013.12
61. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. *J Natl Cancer Inst.* 2011;103(23):1741-1751. doi:10.1093/jnci/djr385
62. Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. *Gastroenterology.* 2008; 135(2):489-498. doi:10.1053/j.gastro.2008.05.039
63. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med.* 2004; 351(26):2704-2714. doi:10.1056/NEJMoa033403

64. Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. *Lancet Oncol.* 2015;16(16):1599-1600. doi:10.1016/S1470-2045(15)00444-1
65. McFarlane M, Millard A, Hall H, et al. Urinary volatile organic compounds and faecal microbiome profiles in colorectal cancer. *Colorectal Dis.* 2019;21(11):1259-1269. doi:10.1111/codi.14739
66. Di Lena M, Porcelli F, Altomare DF. Volatile organic compounds as new biomarkers for colorectal cancer: a review. *Colorectal Dis.* 2016;18(7):654-663. doi:10.1111/codi.13271
67. Batty CA, Cauchi M, Lourenço C, Hunter JO, Turner C. Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal Cancer. *PLoS One.* 2015;10(6):e0130301. Published 2015 Jun 18. doi:10.1371/journal.pone.0130301
68. Bond A, Greenwood R, Lewis S, et al. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. *Aliment Pharmacol Ther.* 2019;49(8):1005-1012. doi:10.1111/apt.15140
69. Ishibe A, Ota M, Takeshita A, et al. Detection of gas components as a novel diagnostic method for colorectal cancer. *Ann Gastroenterol Surg.* 2018;2(2):147-153. Published 2018 Jan 11. doi:10.1002/ags3.12056
70. Amal H, Leja M, Funka K, et al. Breath testing as potential colorectal cancer screening tool. *Int J Cancer.* 2016;138(1):229-236. doi:10.1002/ijc.29701
71. Silaghi A, Constantin VD, Socea B, et al. Inflammatory bowel disease: pathogenesis, diagnosis and current therapeutic approach. *J Mind Med Sci.* 2022;9(1):56-77. doi:10.22543/7674.91.P5677
72. Mateescu MC, Grigorescu S, Socea B, Bloanca V, Grigorescu OD. Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments. *J Pers Med.* 2023;13(2):210. doi:10.3390/jpm13020210
73. Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. *Ann Surg.* 1983;198(6):743-752. doi:10.1097/00000658-198312000-00013
74. Gainant A. Emergency management of acute colonic cancer obstruction. *J Visc Surg.* 2012;149(1):e3-e10. doi:10.1016/j.jvisurg.2011.11.003
75. Cirocchi R, Cesare Campanile F, Di Saverio S, et al. Laparoscopic versus open colectomy for obstructing right colon cancer: A systematic review and meta-analysis. *J Visc Surg.* 2017;154(6):387-399. doi:10.1016/j.jvisurg.2017.09.002
76. Ansaloni L, Andersson RE, Bazzoli F, et al. Guidelinenes in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. *World J Emerg Surg.* 2010;5:29. Published 2010 Dec 28. doi:10.1186/1749-7922-5-29
77. Trompetas V. Emergency management of malignant acute left-sided colonic obstruction. *Ann R Coll Surg Engl.* 2008;90(3):181-186. doi:10.1308/003588408X285757
78. De Salvo GL, Gava C, Pucciarelli S, Lise M. Curative surgery for obstruction from primary left colorectal carcinoma: primary or staged resection?. *Cochrane Database Syst Rev.* 2004;2004(2):CD002101. doi:10.1002/14651858.CD002101.pub2
79. Desai DC, Brennan EJ Jr, Reilly JF, Smink RD Jr. The utility of the Hartmann procedure. *Am J Surg.* 1998;175(2):152-154. doi:10.1016/S0002-9610(97)00272-9
80. Kronborg O. Acute obstruction from tumour in the left colon without spread. A randomized trial of emergency colostomy versus resection. *Int J Colorectal Dis.* 1995;10(1):1-5. doi:10.1007/BF00337576
81. Motofei IG. Biology of cancer: Understanding the supracellular control of mitosis in physiological processes and malignancy [published online ahead of print, 2023 Mar 31]. *Semin Cancer Biol.* 2023;92:42-44. doi:10.1016/j.semcancer.2023.03.010
82. Krstic S, Resanovic V, Alempijevic T, et al. Hartmann's procedure vs loop colostomy in the treatment of obstructive rectosigmoid cancer. *World J Emerg Surg.* 2014;9(1):52. Published 2014 Oct 4. doi:10.1186/1749-7922-9-52
83. Tekkis PP, Kinsman R, Thompson MR, Stamatakis JD; Association of Coloproctology of Great Britain, Ireland. The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer. *Ann Surg.* 2004;240(1):76-81. doi:10.1097/01.sla.0000130723.81866.75
84. Cirocchi R, Arezzo A, Sapienza P, et al. Current Status of the Self-Expandable Metal Stent as a Bridge to Surgery Versus Emergency Surgery in Colorectal Cancer: Results from an Updated Systematic Review and Meta-Analysis of the Literature. *Medicina (Kaunas).* 2021;57(3):268. Published 2021 Mar 15. doi:10.3390/medicina57030268
85. Kim HJ, Choi GS, Park JS, Park SY, Jun SH. Higher rate of perineural invasion in stent-laparoscopic approach in comparison to emergent open resection for obstructing left-sided colon cancer. *Int J Colorectal Dis.* 2013;28(3):407-414. doi:10.1007/s00384-012-1556-x
86. Kim SJ, Kim HW, Park SB, et al. Colonic perforation either during or after stent insertion as a bridge to surgery for malignant colorectal obstruction increases

- the risk of peritoneal seeding. *Surg Endosc.* 2015; 29(12):3499-3506. doi:10.1007/s00464-015-4100-6
87. Sabbagh C, Browet F, Diouf M, et al. Is stenting as "a bridge to surgery" an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a propensity score analysis. *Ann Surg.* 2013;258(1):107-115. doi: 10.1097/SLA.0b013e31827e30ce
 88. Kim MK, Kye BH, Lee IK, et al. Outcome of bridge to surgery stenting for obstructive left colon cancer. *ANZ J Surg.* 2017;87(12):E245-E250. doi:10.1111/ans.13525
 89. Köhler G, Antoniou SA, Lechner M, Mayer F, Mair J, Emmanuel K. Stenting for Emergency Colorectal Obstruction: An Analysis of 204 Patients in Relation to Predictors of Failure and Complications. *Scand J Surg.* 2015;104(3):146-153. doi:10.1177/1457496914552342
 90. Pisano M, Zorcolo L, Merli C, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. *World J Emerg Surg.* 2018;13:36. Published 2018 Aug 13. doi: 10.1186/s13017-018-0192-3
 91. Bass G, Fleming C, Conneely J, Martin Z, Mealy K. Emergency first presentation of colorectal cancer predicts significantly poorer outcomes: a review of 356 consecutive Irish patients. *Dis Colon Rectum.* 2009; 52(4):678-684. doi:10.1007/DCR.0b013e3181a1d8c9
 92. Langell JT, Mulvihill SJ. Gastrointestinal perforation and the acute abdomen. *Med Clin North Am.* 2008; 92(3):599-ix. doi:10.1016/j.mcna.2007.12.004
 93. Zorcolo L, Covotta L, Carlomagno N, Bartolo DC. Safety of primary anastomosis in emergency colorectal surgery. *Colorectal Dis.* 2003;5(3):262-269. doi:10.1046/j.1463-1318.2003.00432.x
 94. Tsai HL, Hsieh JS, et al. Perforated colonic cancer presenting as intra-abdominal abscess. *Int J Colorectal Dis.* 2007;22(1):15-19. doi:10.1007/s00384-006-0097-6
 95. Kim IY, Kim BR, Kim YW. Outcomes of laparoscopic and open surgery for colorectal cancer in the emergency setting. *In Vivo.* 2015;29(2):295-300.
 96. Strate LL. Lower GI bleeding: epidemiology and diagnosis. *Gastroenterol Clin North Am.* 2005;34(4): 643-664. doi:10.1016/j.gtc.2005.08.007
 97. Korsgaard M, Pedersen L, Sørensen HT, Laurberg S. Reported symptoms, diagnostic delay and stage of colorectal cancer: a population-based study in Denmark. *Colorectal Dis.* 2006;8(8):688-695. doi: 10.1111/j.1463-1318.2006.01014.x
 98. Zuccaro G Jr. Management of the adult patient with acute lower gastrointestinal bleeding. American College of Gastroenterology. Practice Parameters Committee. *Am J Gastroenterol.* 1998;93(8):1202-1208. doi:10.1111/j.1572-0241.1998.00395.x
 99. Ofosu A, Ramai D, Latson W, Adler DG. Endoscopic management of bleeding gastrointestinal tumors. *Ann Gastroenterol.* 2019;32(4):346-351. doi: 10.20524/aog.2019.0391
 100. Savides TJ, Jensen DM, Cohen J, et al. Severe upper gastrointestinal tumor bleeding: endoscopic findings, treatment, and outcome. *Endoscopy.* 1996;28(2):244-248. doi:10.1055/s-2007-1005436
 101. Beyazit Y, Onder FO, Torun S, et al. Topical application of ankaferd hemostat in a patient with gastroduodenal amyloidosis complicated with gastrointestinal bleeding. *Blood Coagul Fibrinolysis.* 2013; 24(7):762-765. doi: 10.1097/MBC.0b013e328362d996
 102. Hirao M, Masuda K, Asanuma T, et al. Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. *Gastrointest Endosc.* 1988;34(3):264-269. doi: 10.1016/s0016-5107(88)71327-9
 103. Gomes AS, Lois JF, McCoy RD. Angiographic treatment of gastrointestinal hemorrhage: comparison of vasopressin infusion and embolization. *AJR Am J Roentgenol.* 1986;146(5):1031-37. doi: 10.2214/ajr.146.5.1031
 104. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol.* 2009;27(22):3677-3683. doi:10.1200/JCO.2008.20.5278
 105. Güngören FZ, Erol C, Bilici A, Dayangaç M, Şeker M, Ölmez ÖF, Yaprak O, Yıldız Ö, Öncel M. The comparison of local tumor control after microwave ablation, surgical resection and combined treatment for colorectal liver metastases. *J Mind Med Sci.* 2022;9(1): 125-132. doi:10.22543/7674.91.P125132
 106. Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. *Ann Surg Oncol.* 2007;14(12):3460-3471. doi:10.1245/s10434-007-9557-7
 107. Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. *Ann Oncol.* 2014; 25(3):651-657. doi:10.1093/annonc/mdt591
 108. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet.* 2008;371(9617): 1007-1016. doi:10.1016/S0140-6736(08)60455-9
 109. Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic

- colorectal cancer: a single institution experience. *J Am Coll Surg*. 2013; 216(1):41-49. doi: 10.1016/j.jamcollsurg.2012.08.030
110. Feng Q, Wei Y, Zhu D, et al. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable--a meta-analysis. *PLoS One*. 2014;9(8):e104348. doi: 10.1371/journal.pone.0104348
 111. Adams RB, Aloia TA, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. *HPB (Oxford)*. 2013;15(2):91-103. doi:10.1111/j.1477-2574.2012.00557.x
 112. House MG, Ito H, Gönen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. *J Am Coll Surg*. 2010;210(5): 744-755. doi:10.1016/j.jamcollsurg.2009.12.040
 113. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. *Ann Surg*. 2009; 250(3):440-448. doi:10.1097/SLA.0b013e3181b4539b
 114. Memeo R, de Blasi V, Adam R, et al. Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis. *HPB (Oxford)*. 2016;18(9):781-790. doi:10.1016/j.hpb.2016.06.004
 115. Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival. *Ann Surg*. 2016;263(1):146-152. doi: 10.1097/SLA.0000000000001194
 116. Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. *J Am Coll Surg*. 2013;216(2): 201-209. doi:10.1016/j.jamcollsurg.2012.10.018
 117. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. *N Engl J Med*. 2007;356(15):1545-1559. doi:10.1056/NEJMra065156
 118. Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. *HPB (Oxford)*. 2013;15(7):483-491. doi:10.1111/j.1477-2574.2012.00607.x
 119. Lo WM, Tohme ST, Geller DA. Recent Advances in Minimally Invasive Liver Resection for Colorectal Cancer Liver Metastases-A Review. *Cancers (Basel)*. 2022;15(1):142. Published 2022 Dec 26. doi: 10.3390/cancers15010142
 120. Fretland ÅA, Dagenborg VJ, Waaler Bjørnelv GM, et al. Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases. *Br J Surg*. 2019;106(10):1372-1380. doi: 10.1002/bjs.11227
 121. Kerschner AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. *Br J Cancer*. 2013; 108(7):1432-1439. doi:10.1038/bjc.2013.82
 122. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol*. 2016;17(12):1709-1719. doi:10.1016/S1470-2045(16)30500-9
 123. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg*. 2002;89(12):1545-1550. doi:10.1046/j.1365-2168.2002.02274.x
 124. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. *J Clin Oncol*. 2012;30(3):263-67. doi:10.1200/JCO.2011.37.1039
 125. Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. *Eur J Surg Oncol*. 2012; 38(7):617-623. doi:10.1016/j.ejso.2012.03.008
 126. Sugarbaker PH. Peritonectomy procedures. *Ann Surg*. 1995; 221(1):29-42. doi:10.1097/0000658-199501000-00004
 127. Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. *BJS Open*. 2019;3(5):585-594. doi: 10.1002/bjs.5.50179
 128. Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. *J Am Coll Surg*. 2014;218(4):573-585. doi:10.1016/j.jamcollsurg.2013.12.013
 129. Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. *Ann Surg Oncol*. 2013;20(13):4224-4230. doi:10.1245/s10434-013-3145-9
 130. Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. *Ann*

- Surg Oncol.* 2014;21(5):1501-1505. doi:10.1245/s10434-013-3061-z
131. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol.* 2003; 21(20):3737-3743. doi:10.1200/JCO.2003.04.187
132. Chakedis J, Schmidt CR. Surgical Treatment of Metastatic Colorectal Cancer. *Surg Oncol Clin N Am.* 2018;27(2):377-399. doi:10.1016/j.soc.2017.11.010
133. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. *Ann Thorac Surg.* 2007;84(1):324-338. doi: 10.1016/j.athoracsur.2007.02.093
134. Tampellini M, Ottone A, Bellini E, et al. The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. *Oncologist.* 2012;17(11):1430-38. doi:10.1634/theoncologist.2012-0142
135. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. *Ann Surg Oncol.* 2013;20(2):572-579. doi:10.1245/s10434-012-2726-3